OTCMKTS:STLT

Spotlight Innovation Competitors

$0.01
0.00 (0.00 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.02
$0.02
52-Week Range
$0.00
Now: $0.01
$0.04
VolumeN/A
Average Volume18,626 shs
Market Capitalization$342,900.00
P/E RatioN/A
Dividend YieldN/A
Beta-105.24

Competitors

Spotlight Innovation (OTCMKTS:STLT) Vs. HSTC, AKAOQ, COTQF, PPCB, ANTH, and TLOG

Should you be buying STLT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Spotlight Innovation, including HST Global (HSTC), Achaogen (AKAOQ), Cotinga Pharmaceuticals (COTQF), Propanc Biopharma (PPCB), Anthera Pharmaceuticals (ANTH), and TetraLogic Pharmaceuticals (TLOG).

Spotlight Innovation (OTCMKTS:STLT) and HST Global (OTCMKTS:HSTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Spotlight Innovation and HST Global, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spotlight Innovation0000N/A
HST Global0000N/A

Earnings and Valuation

This table compares Spotlight Innovation and HST Global's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spotlight InnovationN/AN/AN/AN/AN/A
HST GlobalN/AN/A$430,000.00N/AN/A

Profitability

This table compares Spotlight Innovation and HST Global's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spotlight InnovationN/AN/AN/A
HST GlobalN/A-1,715.09%-13,300.29%

Risk & Volatility

Spotlight Innovation has a beta of -105.24, suggesting that its stock price is 10,624% less volatile than the S&P 500. Comparatively, HST Global has a beta of -0.52, suggesting that its stock price is 152% less volatile than the S&P 500.

Summary

Spotlight Innovation beats HST Global on 2 of the 3 factors compared between the two stocks.

Spotlight Innovation (OTCMKTS:STLT) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Spotlight Innovation and Achaogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spotlight Innovation0000N/A
Achaogen0000N/A

Earnings and Valuation

This table compares Spotlight Innovation and Achaogen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spotlight InnovationN/AN/AN/AN/AN/A
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A

Spotlight Innovation has higher earnings, but lower revenue than Achaogen.

Profitability

This table compares Spotlight Innovation and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spotlight InnovationN/AN/AN/A
AchaogenN/AN/AN/A

Volatility & Risk

Spotlight Innovation has a beta of -105.24, meaning that its stock price is 10,624% less volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of Achaogen shares are held by institutional investors. 7.8% of Achaogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Achaogen beats Spotlight Innovation on 4 of the 4 factors compared between the two stocks.

Spotlight Innovation (OTCMKTS:STLT) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Spotlight Innovation and Cotinga Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spotlight Innovation0000N/A
Cotinga Pharmaceuticals0000N/A

Profitability

This table compares Spotlight Innovation and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spotlight InnovationN/AN/AN/A
Cotinga PharmaceuticalsN/AN/AN/A

Risk & Volatility

Spotlight Innovation has a beta of -105.24, suggesting that its stock price is 10,624% less volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, suggesting that its stock price is 4,244% more volatile than the S&P 500.

Earnings and Valuation

This table compares Spotlight Innovation and Cotinga Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spotlight InnovationN/AN/AN/AN/AN/A
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A

Summary

Cotinga Pharmaceuticals beats Spotlight Innovation on 1 of the 1 factors compared between the two stocks.

Propanc Biopharma (OTCMKTS:PPCB) and Spotlight Innovation (OTCMKTS:STLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Propanc Biopharma and Spotlight Innovation, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Propanc Biopharma0000N/A
Spotlight Innovation0000N/A

Profitability

This table compares Propanc Biopharma and Spotlight Innovation's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Propanc BiopharmaN/AN/A-4,812.81%
Spotlight InnovationN/AN/AN/A

Risk & Volatility

Propanc Biopharma has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Spotlight Innovation has a beta of -105.24, suggesting that its stock price is 10,624% less volatile than the S&P 500.

Valuation & Earnings

This table compares Propanc Biopharma and Spotlight Innovation's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A
Spotlight InnovationN/AN/AN/AN/AN/A

Anthera Pharmaceuticals (OTCMKTS:ANTH) and Spotlight Innovation (OTCMKTS:STLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Valuation & Earnings

This table compares Anthera Pharmaceuticals and Spotlight Innovation's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthera PharmaceuticalsN/AN/AN/AN/AN/A
Spotlight InnovationN/AN/AN/AN/AN/A

Profitability

This table compares Anthera Pharmaceuticals and Spotlight Innovation's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthera PharmaceuticalsN/AN/AN/A
Spotlight InnovationN/AN/AN/A

Risk & Volatility

Anthera Pharmaceuticals has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Spotlight Innovation has a beta of -105.24, suggesting that its stock price is 10,624% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Anthera Pharmaceuticals and Spotlight Innovation, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthera Pharmaceuticals0000N/A
Spotlight Innovation0000N/A

Summary

Anthera Pharmaceuticals beats Spotlight Innovation on 1 of the 1 factors compared between the two stocks.

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and Spotlight Innovation (OTCMKTS:STLT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Risk & Volatility

TetraLogic Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Spotlight Innovation has a beta of -105.24, suggesting that its share price is 10,624% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for TetraLogic Pharmaceuticals and Spotlight Innovation, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TetraLogic Pharmaceuticals0000N/A
Spotlight Innovation0000N/A

Profitability

This table compares TetraLogic Pharmaceuticals and Spotlight Innovation's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TetraLogic PharmaceuticalsN/AN/AN/A
Spotlight InnovationN/AN/AN/A

Earnings & Valuation

This table compares TetraLogic Pharmaceuticals and Spotlight Innovation's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A
Spotlight InnovationN/AN/AN/AN/AN/A

Summary

TetraLogic Pharmaceuticals beats Spotlight Innovation on 1 of the 1 factors compared between the two stocks.


Spotlight Innovation Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
HSTC
HST Global
0.8$0.26flat$1.36 millionN/A0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.34 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57High Trading Volume
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21flat$1.12 millionN/A0.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$966,000.00N/A0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$928,000.00N/A0.00
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$876,000.00N/A0.00Gap Down
PXYN
Praxsyn
0.6$0.00flat$848,000.00N/A0.00Gap Down
ATRX
Adhera Therapeutics
0.0$0.06flat$733,000.00$250,000.000.00Gap Down
SPHS
Sophiris Bio
0.1$0.02flat$693,000.00N/A0.00Gap Up
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$572,000.00N/A0.00Gap Down
TRPXD
Therapix Biosciences
0.0$9.00flat$450,000.00N/A0.00High Trading Volume
SKVI
Skinvisible
0.7$0.10flat$425,000.00$40,000.000.00
BSPM
Biostar Pharmaceuticals
0.0$0.16flat$422,000.00N/A0.00Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$358,000.00N/A0.00Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00Gap Up
PZRXQ
PhaseRx
0.2$0.03flat$332,000.00N/A0.00
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.08flat$183,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01flat$83,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$7,000.00$110,000.000.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.10flat$0.00N/A0.00Gap Up
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00News Coverage
ARYX
ARYx Therapeutics
0.0$0.02flat$0.00N/A0.00High Trading Volume
Gap Down
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.02flat$0.00N/A0.00Decrease in Short Interest
Gap Up
HRBR
Harbor Diversified
0.0$1.13flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00Gap Up
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.06flat$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00
PARD
Poniard Pharmaceuticals
0.5$0.06flat$0.00N/A0.00High Trading Volume
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.04flat$0.00N/A0.00Gap Down
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.